Gluten-digesting enzyme pills: what the trials found and what the labels say

Short answer

The Gluten Intolerance Group says no supplement or medication neutralizes gluten, and that a gluten-free diet is currently the only treatment for gluten-related disorders1, 2. The makers of two enzyme capsules say on their own pages that their products are not intended to replace the diet3, 4.

Published by Gluten Verdict · updated · 18 sources, each linked below

Reviewed by Mark Peter, Registered dietitian (RD), on

Open mustard-yellow handbag on a restaurant chair with a small bottle inside.

Key points

  • The Gluten Intolerance Group states that a gluten-free diet is currently the only treatment for gluten-related disorders2.
  • A 2026 review reports that not a single enzyme-based drug has gained regulatory approval for celiac disease5.
  • In a 2015 lab study of five commercial digestive enzyme supplements, the authors concluded the supplements were ineffective in degrading immunogenic gluten epitopes6.
  • Dietary supplement labels that carry a structure/function claim must state that FDA has not evaluated the claim and that the product is not intended to diagnose, treat, cure or prevent any disease7, 8.
  • Each trial result belongs to the enzyme and the conditions that trial used, so read what each study measured before applying it to a capsule.

What the charity and NIH pages say

The Gluten Intolerance Group (GIG) answers the question directly: there are no supplements or medications that “neutralize” or “de-activate” gluten1. It adds that a gluten-free diet is currently the only treatment for gluten-related disorders2.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) says that doctors treat celiac disease by helping people to follow a gluten-free diet9.

GIG also says the scientific community is researching substances that could make consuming small amounts of gluten less problematic, such as what one might get through cross-contact10. A 2026 review of enzyme therapy reports that, after more than two decades of work, not a single enzyme-based drug has gained regulatory approval5.

What celiac organisations say about enzyme products

Coeliac Australia, in its advice about the enzyme supplement GluteGuard, says that gluten degrading enzymes are not medicines designed to treat coeliac disease55. It also says there is currently no product approved as a registered medicine for coeliac disease in Australia56. That is an Australian statement about the Australian register.

Coeliac Australia advises that people with coeliac disease who choose to use GluteGuard must continue to maintain a strict gluten-free diet and not deliberately ingest gluten when using the product57.

The Celiac Disease Foundation, writing in 2015 about the lab study described below, said that based on the research then, caution is advised when considering enzyme supplements and drugs, since it depends on the type of enzyme used and how much research has been completed58.

What products sold as supplements were found to contain and do

Two papers looked at digestive-enzyme and glutenase products that are sold as supplements. They date from 2015 and 2017, so formulas sold today may differ.

A survey of labels, 2017

Researchers reviewed the contents, claims and disclaimers of 14 glutenase products. All contained proteases, eight contained X-prolyl exopeptidase dipeptidyl peptidase IV, two did not state the protease contents, and eight failed to specify the name or origin of all proteases11. Thirteen claimed to degrade immunogenic gluten fragments and four claimed to help alleviate gastrointestinal symptoms associated with eating gluten12. Their disclaimers included not being evaluated by the US Food and Drug Administration and not being intended to diagnose, treat, cure or prevent any disease13.

The authors note that there are glutenases marketed as dietary supplements that have not been demonstrated to digest the toxic epitopes of gluten14. They conclude that the product names make implicit claims that appear to be supported by the claims on labels and websites, for which there is no scientific basis15.

A laboratory test of five products, 2015

In a separate study, five commercially available digestive enzyme supplements were tested in the lab alongside purified enzymes, with enzyme assays and mass spectrometry16. The authors report that the supplements left the nine immunogenic epitopes of two gliadin fragments largely intact, while the purified enzyme AN-PEP degraded all nine in the pH range of the stomach at a much lower dose17. Their conclusion: currently available digestive enzyme supplements are ineffective in degrading immunogenic gluten epitopes6.

Read the study with its disclosure: three of its authors are employed by DSM Food Specialties and were involved in developing the AN-PEP enzyme for gluten degradation18.

The trials, by name, size and what they measured

These are the trials whose PubMed abstracts we read on 2026-11-17; the list is not exhaustive. The abstract is the source for every cell, and the table keeps each study's own wording of what it measured.

Published trials of gluten-degrading enzymes in celiac disease, as their abstracts report them
StudyWho and how manyWhat it measured (primary endpoint where the abstract names one)What the abstract reports
Tack et al., 2013, pilot of AN-PEP14 patients randomised to gluten with AN-PEP or placebo for 2 weeks19Primary endpoint: change in histology on the modified Marsh classification20The primary endpoint was not met, because the placebo group showed no clinical deterioration, which impeded an effect of AN-PEP21
Lähdeaho et al., 2014, phase 2, ALV003 (a mixture of two recombinant gluten-specific proteases given orally)22Adults with biopsy-proven celiac disease: ALV003 n = 20, placebo n = 21, with a daily gluten challenge23Primary end points: villus height to crypt depth ratio and density of intraepithelial lymphocytes24No significant mucosal deterioration in the ALV003 group, and between groups the morphologic changes and intraepithelial lymphocyte counts differed significantly from baseline to week 625; no statistically significant differences in symptoms between groups26
Murray et al., 2017, latiglutenase494 patients with celiac disease and moderate or severe symptoms27Primary end point: change in the villous height to crypt depth ratio28No differences between latiglutenase and placebo on that ratio, intraepithelial lymphocytes or serology; all groups had significant improvements in histologic and symptom scores29
Syage et al., 2017, post hoc analysis of the 2017 trial173 of 398 patients who completed the trial were seropositive at baseline30Symptoms, in subgroups by seropositivity (a post hoc analysis)31A dose-dependent reduction in symptoms in seropositive but not seronegative patients32
Murray et al., 2022, IMGX003 (the paper's title calls it latiglutenase)3350 randomised, 43 completed; a 1200-mg dose against placebo with 2 g of gluten a day for 6 weeks33, 34Primary endpoint: mean change in villus height to crypt depth ratio33−0.04 against −0.35, P = .05733; the abstract concludes IMGX003 reduced gluten-induced intestinal mucosal damage and symptom severity35
Pultz et al., 2021, phase I, TAK-062A dose-escalation study in healthy participants and patients with celiac disease36Gluten degradation under simulated gastric conditions in vitro and in healthy participants37Median gluten degradation from 97% to more than 99% in complex meals with 1–6 g of gluten, 20–65 minutes after the dose38
Stefanolo et al., 2024, exploratory trial of AN-PEP capsules3940 randomised40; four weeks of capsules (GliadinX, AVI Research) at each of three meals a day, or placebo41Average weekly stool gluten immunogenic peptides, among other outcomes42No significant reduction in overall stool concentration; a significantly lower prevalence of patients with severe symptoms in the AN-PEP arm, so the authors call for further research43. The Results give the symptom comparison as the AN-PEP arm against its own run-in period60
2025 meta-analysis of latiglutenaseFive randomised controlled trials, 1003 participants44Outcomes included symptoms and histological findings improvement45No significant improvement in adverse events or histological findings46

The ALV003, latiglutenase and AN-PEP trials enrolled people with celiac disease23, 27, 39; none of the abstracts we read concerns non-celiac gluten sensitivity.

Read the two columns separately. “What it measured” is what the study set out to look at; the last column is what the abstract reported. A study can report no significant change in one measure and a difference in another, as the 2024 trial did43; each paper's authors say what they make of that.

Why a trial result is not a result for the capsule you can buy

Each result above belongs to one enzyme, at the doses and under the conditions that trial used. The trials named their enzyme (ALV003, latiglutenase, IMGX003, TAK-062, AN-PEP). Where an abstract gives a gluten amount, it is specific: 2 g a day in the ALV003 trial47, 2 g a day for six weeks in the IMGX003 trial34, and meals of 1–6 g in the phase I study38.

The 2015 lab study shows how far results can differ between enzymes: five supplements left the immunogenic epitopes largely intact where purified AN-PEP degraded all nine17. A retail capsule that names AN-PEP is a different question from a retail digestive blend, and the only trial above that tested a named retail capsule reported no significant reduction in overall stool gluten peptides41, 43.

One maker's page for an AN-PEP capsule states that AN-PEP is “the only clinically proven enzyme to neutralize gluten before it can enter the small intestine”48. The pilot trial of AN-PEP reported that its primary endpoint was not met, because the placebo group showed no clinical deterioration21, and the 2024 trial reported no significant reduction in stool gluten peptides overall43. We report both and do not rule between them; the point is that “proven” needs a named study, a named outcome and a named number of people.

Reading the wording on an enzyme label

Some glutenase products are marketed as dietary supplements14. FDA says a supplement's structure/function claim may describe the role of an ingredient intended to affect the normal structure or function of the body, for example “calcium builds strong bones”49. These claims are not pre-approved by FDA; the manufacturer must have substantiation that the claim is truthful and not misleading and must notify FDA within 30 days of marketing50.

A label with such a claim must say that FDA has not evaluated the claim7, and that the product is not intended to “diagnose, treat, cure or prevent any disease”, because only a drug can legally make such a claim8.

Wording read on two makers' own pages on 2026-11-17
Maker and wordingWhat sits next to it on the same page
Enzymedica, GlutenEase: “Supports gluten and casein intolerance*”51The asterisk leads to: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”52
Enzymedica, GlutenEase: the enzymes “break down gluten and casein, digesting them before they lead to occasional gas and bloating.*”53“This product is not intended to replace a gluten-free diet for individuals with Celiac Disease.”3
GliadinX: AN-PEP is “the only clinically proven enzyme to neutralize gluten before it can enter the small intestine”48“GliadinX is intended to support, not to replace, a physician prescribed gluten-free diet”4
GliadinX: “GliadinX protects against cross-contamination and accidental gluten ingestion”59“GliadinX is intended to support, not to replace, a physician prescribed gluten-free diet”4
GliadinX: the page's disclaimer“The statements on this website have not been evaluated by the Food and Drug Administration. The FDA only evaluates foods and drugs, not supplements like this product.”54

Two things to look for in any label: the verb (a supplement label may not claim to treat, cure or prevent a disease8, so look at what the verb actually promises; compare “supports” with “protects against” in the table above) and whether the same page states that the product does not replace the diet.

For how to read the rest of a supplement label, including its “other ingredients”, see our guide on how to read a supplement label for gluten.

If you have already eaten gluten

For what is known about the timing and length of symptoms after an exposure, see our guide on how long after eating gluten symptoms start and last.

Questions to put to any enzyme product

  1. Which enzyme is it, by name and source, and how much is in a capsule? In the 2017 label survey, eight of 14 products failed to specify the name or origin of all their proteases11.
  2. Is there a published trial of this exact product, and what was its primary measure?
  3. Who was studied (people with celiac disease or healthy volunteers), how many, and was there a placebo group?
  4. How much gluten was used, and what was measured: biopsy, symptoms, antibodies, or gluten peptides in stool?
  5. Who paid for the study and who wrote it? The 2015 lab study disclosed authors employed by DSM Food Specialties who were involved in developing the AN-PEP enzyme18.
  6. Does the label say the product replaces the gluten-free diet? Both makers read above say their products are not intended to replace it3, 4.

Questions people ask

Can an enzyme pill let someone with celiac disease eat gluten?

GIG says no supplement or medication neutralizes or de-activates gluten1, and the makers of two capsules say their products are not intended to replace the gluten-free diet3, 4.

Has any gluten-degrading enzyme been approved as a drug?

A 2026 review reports that not a single enzyme-based drug has gained regulatory approval5.

Is AN-PEP proven to work?

A maker's page calls AN-PEP the only clinically proven enzyme to neutralize gluten before it can enter the small intestine48. The 2013 pilot trial reported that its primary endpoint was not met, because the placebo group showed no clinical deterioration21, and the 2024 trial of AN-PEP capsules reported no significant reduction in overall stool gluten peptides, with a lower prevalence of severe symptoms in the AN-PEP arm43, which the Results compare with the arm's own run-in period60.

Do digestive enzymes help with gluten sensitivity rather than celiac disease?

GIG states that a gluten-free diet is currently the only treatment for gluten-related disorders2. The ALV003, latiglutenase and AN-PEP capsule trials enrolled people with celiac disease23, 27, 39.

Why do the labels say “supports” instead of “treats”?

FDA requires a supplement label with a structure/function claim to state that the claim has not been evaluated and that the product is not intended to diagnose, treat, cure or prevent any disease, because only a drug can legally make such a claim7, 8.

More in Medications, supplements and non-food products

Sources